BR112015007749A2 - métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica. - Google Patents

métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica.

Info

Publication number
BR112015007749A2
BR112015007749A2 BR112015007749A BR112015007749A BR112015007749A2 BR 112015007749 A2 BR112015007749 A2 BR 112015007749A2 BR 112015007749 A BR112015007749 A BR 112015007749A BR 112015007749 A BR112015007749 A BR 112015007749A BR 112015007749 A2 BR112015007749 A2 BR 112015007749A2
Authority
BR
Brazil
Prior art keywords
hyperkalaemia
methods
kidney disease
chronic kidney
treating hypertension
Prior art date
Application number
BR112015007749A
Other languages
English (en)
Portuguese (pt)
Inventor
Klaerner Gerrit
Berman Lance
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015007749(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Relypsa Inc filed Critical Relypsa Inc
Publication of BR112015007749A2 publication Critical patent/BR112015007749A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
BR112015007749A 2012-10-08 2013-10-08 métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica. BR112015007749A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261711184P 2012-10-08 2012-10-08
PCT/US2013/063921 WO2014058905A2 (en) 2012-10-08 2013-10-08 Potassium-binding agents for treating hypertension and hyperkalemia

Publications (1)

Publication Number Publication Date
BR112015007749A2 true BR112015007749A2 (pt) 2017-07-04

Family

ID=49385427

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015007749A BR112015007749A2 (pt) 2012-10-08 2013-10-08 métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica.

Country Status (10)

Country Link
US (6) US10813946B2 (enExample)
EP (1) EP2916851B1 (enExample)
JP (4) JP6475624B2 (enExample)
KR (2) KR20150088243A (enExample)
CN (2) CN104822383A (enExample)
AU (3) AU2013329451B2 (enExample)
BR (1) BR112015007749A2 (enExample)
CA (1) CA2886788C (enExample)
HK (1) HK1210705A1 (enExample)
WO (1) WO2014058905A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
CA2886788C (en) 2012-10-08 2022-04-19 Relypsa, Inc. Potassium-binding agents for treating hypertension and hyperkalemia
DK3287133T3 (da) 2013-06-05 2019-07-01 Tricida Inc Proton-bindende polymerer til oral indgivelse
KR102625115B1 (ko) 2014-12-10 2024-01-12 트리시다, 인크. 경구 투여용 양성자-결합 폴리머
ITUB20159278A1 (it) * 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
CN105622602A (zh) * 2016-01-30 2016-06-01 合肥华方医药科技有限公司 一种沙坦类小檗碱偶合物制备方法及其医药用途
KR102655774B1 (ko) 2016-05-06 2024-04-05 트리시다, 인크. 산-염기 장애의 치료를 위한 조성물 및 방법
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
US20230126376A1 (en) * 2020-03-27 2023-04-27 Vifor (International) Ltd. Synthesis of methyl 2-fluoroacrylate
CN111978590B (zh) * 2020-09-04 2021-02-12 四川大学 一种沸石-肝素模拟聚合物共混微球、其制备方法及其应用
KR102647158B1 (ko) 2021-03-24 2024-03-15 강원대학교산학협력단 신규한 페디오코커스 악시딜락티시 균주 및 상기 균주를 이용하여 발효시킨 대두 발효물의 다양한 용도
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487958A (en) * 1892-12-13 Patrick mccann
US2340111A (en) 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (enExample) 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4191812A (en) 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3149136A1 (de) 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (fr) 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8817015D0 (en) 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
EP0464299B1 (en) 1990-07-04 1995-01-11 Marcin Krotkiewski Antihypertensive preparation
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
SK31395A3 (en) 1992-08-20 1995-08-09 Du Pont Crosslinked polymeric ammonium salts
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
WO1994027619A1 (en) 1993-05-20 1994-12-08 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
FI962203A7 (fi) 1993-11-25 1996-07-22 Salternate B V Monovalentteja kationeja sitovia hiukkasia, hiukkasten käyttö sekä men etelmiä natrium- ja/tai kaliumonien huuhtelemiseksi ja poistamiseksi
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
AU3585397A (en) 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
KR100440544B1 (ko) 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
EP1126880A2 (en) 1998-11-06 2001-08-29 G.D. SEARLE & CO. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
CA2355829A1 (en) 1999-01-07 2000-07-13 Louise Templeton Multiparticulate oral dosage forms
US20020054903A1 (en) 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US6569910B1 (en) 1999-10-27 2003-05-27 Basf Aktiengesellschaft Ion exchange resins and methods of making the same
EP1249240A4 (en) 2000-01-14 2003-03-19 Otsuka Pharma Co Ltd INHIBITORS OF SODIUM ION ABSORPTION, AND PROPHYLACTIC OR THERAPEUTIC AGENTS AND FOOD PRODUCTS CONTAINING SAID INHIBITORS
FR2812632B1 (fr) 2000-08-07 2003-03-07 Solvay Procede pour la synthese de composes fluoroorganiques
EP2324861A1 (en) 2000-11-20 2011-05-25 Sorbent Therapeutics, Inc. In vivo use of water absorbent polymers
WO2002062356A2 (en) 2001-02-06 2002-08-15 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
MY139380A (en) 2001-10-01 2009-09-30 Basf Ag Process for the preparation of alkylaryl compounds and sulfonates thereof
JP2004149525A (ja) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
ES2396679T3 (es) 2003-02-25 2013-02-25 Dupont Nutrition Biosciences Aps Un sistema de lecho móvil simulado
JP2007517047A (ja) 2003-12-31 2007-06-28 ジェンザイム・コーポレーション 腸溶コーティングされた脂肪族アミンポリマーの胆汁酸捕捉因子
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
CA2557848C (en) 2004-03-30 2013-12-10 Ilypsa, Inc. Ion binding compositions
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
CA2624170C (en) * 2005-09-30 2014-02-25 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
AU2006294455B2 (en) 2005-09-30 2013-06-20 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US20070248564A1 (en) 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
WO2009029841A1 (en) 2007-08-29 2009-03-05 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
US20100111892A1 (en) 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
AU2009282721B2 (en) * 2008-08-22 2015-10-29 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2010132662A1 (en) * 2009-05-13 2010-11-18 Relypsa, Inc. Powder formulations of potassium-binding active agents
PT2550305T (pt) 2010-03-20 2018-04-20 Relypsa Inc Processo contínuo para preparar partículas de polifluoroacrilato
US10557856B2 (en) * 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US8697132B2 (en) * 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
WO2012097011A1 (en) 2011-01-10 2012-07-19 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation- binding polymers and a base, uses thereof
PT2673237T (pt) * 2011-02-11 2019-02-01 Zs Pharma Inc Utilização do silicato de zircónio no tratamento da hipercalemia
JP5976106B2 (ja) 2011-06-27 2016-08-23 レリプサ， インコーポレイテッド ポリマーエステルをポリマー酸に変換するプロセス
WO2013003495A2 (en) 2011-06-27 2013-01-03 Relypsa, Inc. Fluorination of acrylate esters and derivatives
CN110051686A (zh) 2012-07-19 2019-07-26 瑞立普萨公司 包含交联阳离子结合聚合物的组合物
CA2886788C (en) 2012-10-08 2022-04-19 Relypsa, Inc. Potassium-binding agents for treating hypertension and hyperkalemia

Also Published As

Publication number Publication date
JP2018048211A (ja) 2018-03-29
AU2018260862A1 (en) 2018-12-06
JP7113871B2 (ja) 2022-08-05
AU2020294307A1 (en) 2021-02-18
EP2916851A2 (en) 2015-09-16
US9925212B2 (en) 2018-03-27
KR20150088243A (ko) 2015-07-31
CN119405686A (zh) 2025-02-11
WO2014058905A3 (en) 2014-10-30
AU2020294307B2 (en) 2022-06-02
CA2886788A1 (en) 2014-04-17
US9492476B2 (en) 2016-11-15
US20180193377A1 (en) 2018-07-12
US20170020916A1 (en) 2017-01-26
US10813946B2 (en) 2020-10-27
CA2886788C (en) 2022-04-19
US20210038636A1 (en) 2021-02-11
KR20210005314A (ko) 2021-01-13
JP6475624B2 (ja) 2019-02-27
CN104822383A (zh) 2015-08-05
US11123363B2 (en) 2021-09-21
JP2021095421A (ja) 2021-06-24
US20140105848A1 (en) 2014-04-17
JP2016500672A (ja) 2016-01-14
AU2018260862B2 (en) 2020-10-08
US20150110886A1 (en) 2015-04-23
WO2014058905A2 (en) 2014-04-17
AU2013329451A1 (en) 2015-04-23
US20210046104A1 (en) 2021-02-18
JP2020176155A (ja) 2020-10-29
HK1210705A1 (en) 2016-05-06
EP2916851B1 (en) 2025-12-17
JP6817185B2 (ja) 2021-01-20
AU2013329451B2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
BR112015007749A2 (pt) métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica.
BR112015002599A2 (pt) bauleto para motocicletas.
BR302012000171S1 (pt) Configuração aplicada em copo para bebida.
BR302012005407S1 (pt) Configuração aplicada em banco.
HUE045723T2 (hu) Módszerek vesebetegség kimutatására
BR302012005910S1 (pt) Configuração aplicada em farol para motocicleta.
PL2875049T3 (pl) Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd)
CL2016000447A1 (es) Marcadores de riesgo para cardiovasculopatías en pacientes con nefropatía crónica.
FR2972076B1 (fr) Actionneur magnetothermique.
BR112014028306A2 (pt) métodos para tratamento de câncer gástrico.
FR2978994B1 (fr) .
ES1074363Y (es) Cerradura para batientes.
ES1075930Y (es) Grua para andamios.
ES1075966Y (es) Jaula para perdices.
FR2980994B1 (fr) Prehenseur multi-plaquettes.
ES1073873Y (es) Pernio hidráulico para puertas.
ES1074130Y (es) Maceta para plantas.
ES1075484Y (es) Montura adaptable para equitación.
DK2928461T3 (da) Behandling til kronisk nyresygdom
CL2015000298A1 (es) Perfil para construccion.
ES1078738Y (es) Bovedilla para forjados.
ES1078176Y (es) Lastre para emisarios submarinos.
IT1403504B1 (it) Cinta perfezionata.
ITAN20120039A1 (it) Remo per imbarcazioni.
IT1403501B1 (it) Paranuca per casco.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIFOR (INTERNATIONAL) LTD. (CH)

B25C Requirement related to requested transfer of rights

Owner name: VIFOR (INTERNATIONAL) LTD. (CH)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210065411 DE 19/07/2021, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA CESSIONARIA QUE CONSTA NA PROCURACAO E O NOME QUE APARECE NO DOCUMENTO DE CESSAO APRESENTADO. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25C Requirement related to requested transfer of rights

Owner name: VIFOR (INTERNATIONAL) LTD. (CH)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210106067 DE 17/11/2021, E NECESSARIO APRESENTAR PROCURACAO EM NOME DA CESSIONARIA. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.